GO:0015780 nucleotide-sugar transmembrane transport: Golgi Glycosylation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015780 nucleotide-sugar transmembrane transport describes the movement of activated sugar donors such as UDP-galactose, UDP-N-acetylglucosamine and GDP-mannose across intracellular membranes, most prominently into the Golgi lumen.
• The process is executed by nucleotide sugar transporters (NSTs), polytopic membrane proteins belonging to the drug/metabolite transporter superfamily and largely encoded by the SLC35 gene family.
• NSTs are essential for glycosylation, proteoglycan biosynthesis and glycolipid assembly because glycosyltransferases inside the Golgi require lumenal nucleotide sugars that cannot be synthesized there.
• Several SLC35 transporters are bifunctional or multispecific; for example, human and Drosophila UDP-galactose transporters also transport UDP-N-acetylgalactosamine.
• Mutations in SLC35 family genes cause congenital disorders of glycosylation and contribute to cancer, immune dysfunction and neurological disease, making NSTs attractive experimental targets.
• CRISPR knockout, point-mutation knock-in, tagged knock-in and overexpression models combined with glycomics and transporter assays are the standard toolkit for dissecting NST function.
Description
Nucleotide-sugar transmembrane transport (GO:0015780) is the biological process by which activated sugar donors, such as UDP-galactose, UDP-N-acetylglucosamine, UDP-glucuronic acid, GDP-mannose and CMP-sialic acid, are translocated across cellular membranes. The best-characterized example is the delivery of nucleotide sugars from the cytosol into the lumen of the Golgi apparatus, where glycosyltransferases use them as substrates for the assembly of glycoproteins, glycolipids and proteoglycans. Because nucleotide sugars are synthesized in the cytosol and cannot diffuse across lipid bilayers, dedicated carrier proteins are required to supply the secretory pathway. The proteins that mediate this process are known as nucleotide sugar transporters (NSTs). They were molecularly identified in the late 1990s and are now recognized as members of the drug/metabolite transporter superfamily, with most human NSTs encoded by the SLC35 gene family. NSTs are polytopic membrane proteins that typically function as antiporters, exchanging a nucleotide sugar for a nucleoside monophosphate such as UMP or GMP, thereby coupling import to the export of a by-product. Their activity is indispensable for normal glycosylation, and loss of individual NSTs produces selective glycosylation defects rather than a global shutdown of the secretory pathway. For researchers, GO:0015780 matters because it sits at the intersection of metabolism, organelle biology and human disease. Defects in nucleotide sugar transport underlie congenital disorders of glycosylation, immune dysregulation, neurological phenotypes and cancer-associated glycosylation changes. Studying this process requires tools that can quantify transporter activity, glycan composition and organelle-specific nucleotide sugar pools, and CRISPR-based models are increasingly used to link specific SLC35 genes to defined glycosylation outcomes.
nucleotide-sugar transmembrane transport At A Glance
| GO ID | GO:0015780 |
|---|---|
| GO term | nucleotide-sugar transmembrane transport |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Translocation of activated nucleotide sugar donors across intracellular membranes, principally into the Golgi lumen, to supply glycosyltransferases |
| Representative transporters | SLC35 family members including SLC35A1, SLC35A2, SLC35A3, SLC35B1-B4, SLC35C1, SLC35D1-D2 and SLC35E1-E4 |
| Protein family | Drug/metabolite transporter superfamily; polytopic membrane proteins |
| Typical mechanism | Antiport of a nucleotide sugar against a nucleoside monophosphate |
| Cellular location | Golgi apparatus and endoplasmic reticulum membranes |
| Disease relevance | Congenital disorders of glycosylation, immune defects, neurological disease and cancer |
What Is GO:0015780?
In our own words, GO:0015780 nucleotide-sugar transmembrane transport is the directed movement of nucleotide sugars, which are sugar molecules covalently linked to a nucleotide diphosphate or monophosphate carrier, across a biological membrane. It encompasses the transport of substrates such as UDP-galactose, UDP-N-acetylglucosamine, UDP-glucuronic acid, GDP-mannose and CMP-sialic acid from one membrane-bounded compartment to another, most classically from the cytosol into the lumen of the Golgi apparatus or the endoplasmic reticulum. The process is mediated by integral membrane transporter proteins, often acting as antiporters, and it is a prerequisite for the glycosylation reactions that occur inside the secretory pathway.
Why Is nucleotide-sugar transmembrane transport Important in Cell Biology?
Nucleotide-sugar transmembrane transport is important because it controls the supply of substrates for nearly all glycosylation reactions in the secretory pathway. Without NST activity, glycosyltransferases in the Golgi lumen cannot access the nucleotide sugars they need, leading to defective glycoprotein, glycolipid and proteoglycan biosynthesis. This process therefore influences cell surface recognition, signaling, cell adhesion, immune function and extracellular matrix assembly. Clinically, mutations in SLC35 genes cause congenital disorders of glycosylation and have been linked to cancer and neurological phenotypes, making GO:0015780 a focal point for both basic glycobiology and translational research.
• Supplies UDP-galactose, UDP-N-acetylglucosamine, GDP-mannose, CMP-sialic acid and other donors to Golgi glycosyltransferases.
• Required for N-linked and O-linked protein glycosylation, glycosphingolipid synthesis and proteoglycan assembly.
• Loss of individual SLC35 transporters causes selective glycosylation defects and congenital disorders of glycosylation.
• SLC35A2 and other family members have been implicated in neurological disease and epilepsy syndromes.
• Altered nucleotide sugar transport contributes to cancer-associated glycosylation changes and immune dysfunction.
• NSTs are potential drug targets because their activity can be modulated to reshape cell surface glycans.
• The process is experimentally tractable using radioactive or fluorescent nucleotide sugar uptake assays.
• CRISPR screens can identify which SLC35 genes are required for specific glycosylation pathways.
• Nucleotide sugar transport is conserved from yeast to humans, enabling comparative studies.
• Understanding GO:0015780 supports biopharmaceutical glycoengineering of therapeutic proteins.
What Happens During nucleotide-sugar transmembrane transport?
Synthesis of nucleotide sugars in the cytosol
In simple terms: Sugar donors are built in the cytosol before they can be moved into the Golgi.
Nucleotide sugars such as UDP-galactose, UDP-N-acetylglucosamine, UDP-glucuronic acid, GDP-mannose and CMP-sialic acid are synthesized in the cytosol by dedicated enzymes. Because these charged, hydrophilic molecules cannot freely cross lipid bilayers, their accumulation in the cytosol creates a concentration gradient that must be relieved by transport into the secretory pathway. The identity and abundance of cytosolic nucleotide sugars therefore set the upper limit on how much substrate can be delivered to the Golgi lumen.
Recognition and binding by nucleotide sugar transporters
In simple terms: Transporter proteins in the Golgi membrane recognize and grab the sugar donors.
Nucleotide sugar transporters are polytopic membrane proteins that belong to the drug/metabolite transporter superfamily and are mostly encoded by SLC35 genes. They possess multiple transmembrane helices that form a substrate-binding pocket and a translocation pathway. Substrate recognition is selective but not always absolute; for example, human and Drosophila UDP-galactose transporters also accept UDP-N-acetylgalactosamine, indicating overlapping specificities. This binding step determines which nucleotide sugars enter which organelle.
Antiport translocation across the Golgi membrane
In simple terms: The transporter swaps the sugar donor for a waste nucleotide, moving the sugar inside.
Most characterized NSTs function as antiporters, coupling the import of a nucleotide sugar to the export of a nucleoside monophosphate such as UMP or GMP. This exchange mechanism allows the transporter to use the lumenal concentration of the monophosphate as a driving force while preventing excessive accumulation of charged metabolites. The result is a net transfer of activated sugar into the Golgi lumen, where it becomes available to glycosyltransferases.
Delivery to glycosyltransferases and glycan assembly
In simple terms: Once inside, the sugar is used to build the sugar chains on proteins and lipids.
Inside the Golgi lumen, nucleotide sugars serve as substrates for glycosyltransferases that sequentially add monosaccharides to growing glycan chains on proteins, lipids and proteoglycans. The spatial organization of NSTs and glycosyltransferases within Golgi cisternae helps ensure that the correct sugars are available at the correct stage of glycan maturation. Defects in transport therefore produce glycan truncation or altered branching rather than a complete absence of glycosylation.
Recycling and homeostasis of nucleotide sugar pools
In simple terms: The cell balances how much sugar is made, moved and broken down.
Nucleotide sugar transport is integrated with cytosolic synthesis, lumenal hydrolysis and salvage pathways to maintain steady-state pools. The antiport reaction returns nucleoside monophosphates to the cytosol, where they can be recycled or degraded. This homeostasis is important because imbalances in nucleotide sugar supply can alter glycosylation independently of glycosyltransferase expression.
Key Genes Involved in GO:0015780 nucleotide-sugar transmembrane transport
The genes most directly associated with GO:0015780 encode nucleotide sugar transporters, predominantly members of the SLC35 family, together with related proteins that define substrate specificity and organelle targeting.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC35A1 | CMP-sialic acid transporter in the Golgi | Models sialylation defects and immune phenotypes |
| SLC35A2 | UDP-galactose transporter | Linked to congenital disorders of glycosylation and epilepsy |
| SLC35A3 | UDP-N-acetylglucosamine transporter | Studied for Golgi glycosylation and development |
| SLC35A4 | Orphan nucleotide sugar transporter | Emerging target for functional characterization |
| SLC35B1 | UDP-xylose / UDP-galactose related transport | Proteoglycan and glycosaminoglycan research |
| SLC35B2 | PAPS transporter (related nucleotide sulfate transport) | Sulfation and Golgi homeostasis studies |
| SLC35B3 | PAPS transporter | Sulfation pathway models |
| SLC35B4 | UDP-xylose and UDP-N-acetylglucosamine transport | Glycosaminoglycan biosynthesis |
| SLC35C1 | GDP-fucose transporter | Leukocyte adhesion deficiency type II models |
| SLC35D1 | UDP-glucuronic acid / UDP-N-acetylgalactosamine transporter | Proteoglycan and cartilage biology |
| SLC35D2 | UDP-N-acetylglucosamine transporter | Golgi glycosylation studies |
| SLC35E1 | Orphan SLC35 member | Candidate for CRISPR screening |
| SLC35E2 | Orphan SLC35 member | Candidate for functional genomics |
| SLC35E3 | Orphan SLC35 member | Candidate for glycosylation studies |
| SLC35E4 | Orphan SLC35 member | Candidate for transporter discovery |
| UGP2 | UDP-glucose pyrophosphorylase, supplies UDP-glucose | Upstream nucleotide sugar synthesis |
| GALE | UDP-galactose 4-epimerase | Interconverts UDP-galactose and UDP-glucose |
How Is nucleotide-sugar transmembrane transport Regulated?
Nucleotide-sugar transmembrane transport is regulated at multiple levels. Transcription of SLC35 genes can be modulated by cellular differentiation and stress, while transporter activity depends on substrate availability, membrane lipid environment and organelle pH. The antiport mechanism itself provides a form of feedback regulation, because accumulation of lumenal nucleoside monophosphates can influence transport rates. In addition, cross-talk between cytosolic nucleotide sugar synthesis and Golgi transport ensures that glycosylation capacity matches metabolic supply. Although mechanistic details remain incompletely understood, the process is clearly responsive to changes in glycosylation demand and secretory pathway homeostasis.
nucleotide-sugar transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC35A2 | Congenital disorder of glycosylation with neurological involvement | Knockout and point-mutation knock-in in neuronal cell lines |
| SLC35C1 | Leukocyte adhesion deficiency type II | Knockout in immune cell lines and primary leukocytes |
| SLC35A1 | Sialylation defects and immune dysfunction | Knockout in epithelial and immune cells |
| SLC35D1 | Proteoglycan and skeletal abnormalities | Knockout in chondrocyte-like cells |
| SLC35A3 | Developmental and neurological phenotypes | Knockout and overexpression in neural models |
Congenital disorders of glycosylation
Mutations in SLC35 genes cause congenital disorders of glycosylation, a group of inherited diseases characterized by defective protein and lipid glycosylation. SLC35A2 defects in particular have been associated with developmental delay, seizures and abnormal glycosylation profiles. These disorders illustrate that a single transporter can be rate-limiting for specific glycosylation reactions even when other NSTs remain functional.
Immune dysfunction and leukocyte adhesion deficiency
SLC35C1 encodes the GDP-fucose transporter, and its loss impairs fucosylation of selectin ligands, causing leukocyte adhesion deficiency type II. This condition demonstrates how nucleotide sugar transport directly controls immune cell trafficking and inflammation. Similar transport defects can affect other immune glycans and alter host-pathogen interactions.
Cancer-associated glycosylation changes
Altered expression of SLC35 transporters has been observed in cancer and can contribute to tumor-associated glycan signatures that influence proliferation, invasion and immune evasion. Because nucleotide sugar transport shapes cell surface glycans, it is considered a potential therapeutic target for glycoengineering and drug development.
Neurological and developmental phenotypes
Several SLC35 family members, including SLC35A2 and SLC35A3, have been linked to neurological and developmental phenotypes in patients and model systems. The mechanisms likely involve defective glycosylation of neuronal membrane proteins and lipids, although the precise pathways remain under investigation.
From nucleotide-sugar transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a specific SLC35 gene required for Golgi glycosylation? | CRISPR knockout cell line followed by glycomics |
| Does a patient variant impair transporter activity? | Point-mutation knock-in expressing the variant |
| Where does the transporter localize within the cell? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression increase nucleotide sugar transport? | Stable overexpression cell line with uptake assay |
| Which transporters supply a specific glycan epitope? | CRISPR library screening with lectin or antibody readout |
| Can transport be rescued by a wild-type allele? | Knock-in of wild-type cDNA into a knockout background |
How to Study the nucleotide-sugar transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive nucleotide sugar uptake | Transporter activity and kinetics | Validating SLC35 function in Golgi vesicles |
| Mass spectrometry glycomics | Glycan composition and structure | Assessing glycosylation defects in knockout cells |
| Lectin blotting / flow cytometry | Cell surface glycan epitopes | Screening for glycosylation changes |
| Fluorescence microscopy | Subcellular localization of transporters | Confirming Golgi targeting of tagged NSTs |
| CRISPR knockout screening | Gene requirement for a glycan phenotype | Identifying novel SLC35 transporters |
| qPCR / RNA-seq | Expression of SLC35 genes | Correlating transporter expression with glycosylation state |
| Proteomics | Protein interactions and abundance | Mapping NST complexes and glycosyltransferase networks |
Transport uptake assays
Radioactive or fluorescent nucleotide sugar uptake assays using isolated Golgi vesicles or permeabilized cells remain the gold standard for measuring NST activity. These assays can determine substrate specificity, kinetics and inhibitor sensitivity, and they are often used to validate CRISPR-generated transporter mutants.
Glycomics and lectin profiling
Mass spectrometry-based glycomics and lectin blotting reveal how loss or gain of a nucleotide sugar transporter changes protein and lipid glycosylation. These methods are essential for linking a specific SLC35 gene to a defined glycan phenotype and for confirming that transport defects produce selective glycosylation changes.
Imaging and organelle biology
Fluorescent tagging of NSTs and Golgi markers allows researchers to assess subcellular localization, trafficking and co-localization with glycosyltransferases. Live-cell imaging can reveal dynamic changes in Golgi organization when nucleotide sugar transport is perturbed.
CRISPR screening and functional genomics
Pooled CRISPR knockout screens combined with lectin staining or glycan-specific reporters can identify which SLC35 genes are required for particular glycosylation pathways. Follow-up validation using single-gene knockouts and rescue experiments establishes causality.
How CRISPR Can Be Used to Study GO:0015780 nucleotide-sugar transmembrane transport
Knockout
CRISPR knockout of individual SLC35 genes is the most direct way to test whether a transporter is required for a specific glycosylation reaction. Knockout cell lines can be analyzed by glycomics, lectin staining and uptake assays to define the transport defect. Because NSTs often have overlapping specificities, single knockouts may produce subtle phenotypes that require careful assay design.
Point Mutation
Point-mutation knock-in is used to model patient variants or to dissect residues required for substrate binding and antiport. By introducing a single amino acid change into the endogenous SLC35 locus, researchers can separate loss of transport activity from loss of protein expression or localization.
Knock-in
Knock-in of fluorescent or epitope tags allows endogenous NSTs to be tracked in living cells without overexpression artifacts. Knock-in of wild-type cDNA into a knockout background can also serve as a rescue experiment to confirm that the observed phenotype is due to the targeted gene.
Overexpression
Overexpression of a nucleotide sugar transporter can increase flux into a specific glycosylation pathway and is used to test gain-of-function effects. This approach is particularly useful for orphan SLC35 members whose substrates are unknown, because increased transport may produce a detectable glycan signature.
How EDITGENE Supports nucleotide-sugar transmembrane transport Research
Researchers studying nucleotide-sugar transmembrane transport-related genes often need to determine whether a candidate SLC35 transporter is causally involved in a specific glycosylation pathway, disease phenotype or drug response. Establishing causality requires precise genetic models that can isolate transporter function from compensatory changes, and CRISPR-based cell engineering provides the necessary specificity and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for nucleotide-sugar transmembrane transport research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLC35D2 Knockout HEK293 Cell Line | EDJ-KQ7258 | Human | 11046 | Details Get a Quote |
| SLC35D1 Knockout HEK293 Cell Line | EDJ-KQ7872 | Human | 23169 | Details Get a Quote |
| SLC35D2 Knockout A-549 Cell Line | EDJ-KQ32265 | Human | 11046 | Details Get a Quote |
| SLC35D2 Knockout HCT 116 Cell Line | EDJ-KQ32266 | Human | 11046 | Details Get a Quote |
| SLC35D2 Knockout HeLa Cell Line | EDJ-KQ32267 | Human | 11046 | Details Get a Quote |
| SLC35D1 Knockout A-549 Cell Line | EDJ-KQ33451 | Human | 23169 | Details Get a Quote |
| SLC35D1 Knockout HCT 116 Cell Line | EDJ-KQ33452 | Human | 23169 | Details Get a Quote |
| SLC35D1 Knockout HeLa Cell Line | EDJ-KQ33453 | Human | 23169 | Details Get a Quote |
| SLC35D1 Knockout Huh-7 Cell Line | EDC08352 | Human | 23169 | Details Get a Quote |
Displaying Records 1 To 9 Of 9 Records
Frequently Asked Questions About nucleotide-sugar transmembrane transport
What is nucleotide-sugar transmembrane transport?
It is the biological process GO:0015780 in which activated sugar donors such as UDP-galactose and GDP-mannose are moved across intracellular membranes, most commonly into the Golgi lumen, by dedicated transporter proteins.
What genes are involved in nucleotide-sugar transmembrane transport?
The main genes are SLC35 family members, including SLC35A1, SLC35A2, SLC35A3, SLC35B1-B4, SLC35C1, SLC35D1-D2 and SLC35E1-E4, which encode nucleotide sugar transporters.
Why is nucleotide-sugar transmembrane transport important for glycosylation?
Glycosyltransferases inside the Golgi require nucleotide sugars as substrates, but these charged molecules cannot cross membranes on their own, so transport is essential for protein, lipid and proteoglycan glycosylation.
What diseases are linked to nucleotide-sugar transmembrane transport?
Defects in SLC35 transporters cause congenital disorders of glycosylation, leukocyte adhesion deficiency type II, neurological phenotypes and cancer-associated glycosylation changes.
How do nucleotide sugar transporters work?
Most NSTs act as antiporters, exchanging a nucleotide sugar into the Golgi lumen for a nucleoside monophosphate such as UMP or GMP moving out.
Which transporter moves UDP-galactose into the Golgi?
SLC35A2 encodes a UDP-galactose transporter, and related transporters such as the Drosophila UDP-galactose transporter can also transport UDP-N-acetylgalactosamine.
What is the SLC35 family?
The SLC35 family is a group of genes encoding nucleotide sugar transporters, most of which belong to the drug/metabolite transporter superfamily and localize to the Golgi or endoplasmic reticulum.
How can I study nucleotide-sugar transmembrane transport in the lab?
Common methods include radioactive or fluorescent uptake assays, glycomics, lectin profiling, imaging of tagged transporters and CRISPR knockout screens.
What is the role of SLC35A2 in disease?
SLC35A2 mutations have been associated with congenital disorders of glycosylation and neurological phenotypes such as epilepsy and developmental delay.
Can CRISPR be used to model nucleotide sugar transport defects?
Yes, CRISPR knockout, point-mutation knock-in, tagged knock-in and overexpression models are widely used to study SLC35 gene function and glycosylation outcomes.
Conclusion
GO:0015780 nucleotide-sugar transmembrane transport is a central biological process that supplies activated sugar donors to the secretory pathway and thereby controls glycosylation of proteins, lipids and proteoglycans. The SLC35 family of nucleotide sugar transporters mediates this process, and their dysfunction causes congenital disorders of glycosylation, immune defects and cancer-associated glycan changes. Continued research using CRISPR models, glycomics and transport assays will clarify how individual transporters contribute to health and disease and may reveal new therapeutic opportunities.
References
- 1. Berninsone PM et al.. 2000. Nucleotide sugar transporters of the Golgi apparatus.. Curr Opin Struct Biol 10(5):542-7 PMID: 11042451
- 2. Gerardy-Schahn R et al.. 2001. Nucleotide sugar transporters: biological and functional aspects.. Biochimie 83(8):775-82 PMID: 11530210
- 3. Jack DL et al.. 2001. The drug/metabolite transporter superfamily.. Eur J Biochem 268(13):3620-39 PMID: 11432728
- 4. Song Z. 2013. Roles of the nucleotide sugar transporters (SLC35 family) in health and disease.. Mol Aspects Med 34(2-3):590-600 PMID: 23506892
- 5. Kawakita M et al.. 1998. Nucleotide sugar transporters: elucidation of their molecular identity and its implication for future studies.. J Biochem 123(5):777-85 PMID: 9562605
- 6. Sosicka P et al.. 2017. An insight into the orphan nucleotide sugar transporter SLC35A4.. Biochim Biophys Acta Mol Cell Res 1864(5):825-838 PMID: 28167211
- 7. Maszczak-Seneczko D et al.. 2022. Delivery of Nucleotide Sugars to the Mammalian Golgi: A Very Well (un)Explained Story.. Int J Mol Sci 23(15) PMID: 35955785
- 8. Segawa H et al.. 2002. Human and Drosophila UDP-galactose transporters transport UDP-N-acetylgalactosamine in addition to UDP-galactose.. Eur J Biochem 269(1):128-38 PMID: 11784306
